Oruka Therapeutics ORKA Institutional Ownership

Updated Oct 11, 2026

Oruka Therapeutics, Inc. (NASDAQ:ORKA) was reported as a holding by 255 institutional investors in 13F filings for the quarter ended June 30, 2026.

• Total shares held in ORKA rose 41.59% from Q1 2026; the number of holders rose 218.75% from Q2 2025.
• Of the 255 holders of ORKA in Q2 2026, 194 added to their positions, 47 reduced their stakes and 14 left their positions unchanged.
• Altogether, institutional holders owned 74.11Mn ORKA shares at the end of Q2 2026, up 21.77Mn from the prior quarter and up 39.89Mn from a year earlier.
• FMR LLC held the largest position in ORKA at 9.06Mn shares as of June 30, 2026.
• The biggest increases in ORKA positions during Q2 2026 came from FMR LLC (+1.63Mn shares), BlackRock, Inc. (+1.46Mn shares), Bellevue Group AG (+1.15Mn shares), RTW Investments, LP (+1.08Mn shares) and BNP Paribas Financial Markets (+1.07Mn shares).
• Holders that trimmed the most shares of Oruka Therapeutics in Q2 2026 while keeping a position were Viking Global Investors LP (-1.16Mn shares), Mercer Global Advisors Inc (-801.39K shares), Remedium Capital Partners, LLC (-323.45K shares), Woodline Partners LP (-289.63K shares) and Paradigm Biocapital Advisors LP (-175.79K shares).
• Per Business Quant, the top 10 investors in ORKA for the quarter ended June 30, 2026 were FMR LLC (9.06Mn shares), BlackRock, Inc. (4.99Mn shares), Venrock Adviser, LLC (4.15Mn shares), Fairmount Funds Management LLC (3.71Mn shares), Capital World Investors (3.4Mn shares), RTW Investments, LP (3.14Mn shares), State Street Corp (2.67Mn shares), Vanguard Capital Management LLC (2.36Mn shares), Paradigm Biocapital Advisors LP (2.14Mn shares) and Deep Track Capital, LP (1.93Mn shares).